Method for treating gefitinib resistant cancer
US10596162B2 · kind B2 · utility
2Cited by
52References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 11, 2016 |
| Grant date | Mar 24, 2020 |
| Priority date | — |
| Expiry date | Jul 11, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.